U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 26

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated June 19, 2008,
1. Sentara Louise Obici Memorial Hospital d/b/a Sentara Obici Hospital	3. License number 45-18195-01 is amended in its entirety to read as follows:
2. P.O. Box 1100 Suffolk, Virginia 23439	4. Expiration date October 31, 2014
	5. Docket No. 030-14647 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.5 curies
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 10 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
D. In vitro studies.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 2800 Godwin Boulevard, Suffolk, Virginia.

11. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user and/or authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.14.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
45-18195-01

Docket or Reference Number
030-14647

Amendment No. 26

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Hussein M. Aboulatta, M.D.	35.200
Shoaib Bakht, M.D.	35.200
Robert J. D'Haem, M.D.	35.100; 35.200; 35.300; *In vitro* studies
Bhavdeep K. Gupta, M.D.	35.200
Dixon M. Rollins, M.D.	35.100; 35.200; *In vitro* studies
Apurva M. Patel	35.100; 35.200; *In vitro* studies
Andrew P. Zasada, M.D.	35.100; 35.200; 35.300; *In vitro* studies
Edward M. Lynch, M.D.	35.200
Stafford G. Brown, II, M.D.	35.100; 35.200
Victor C. Archie, M.D.	35.300
Song Kuk Kang, M.D.	35.300
Michael L. Miller, D.O.	Oral administration of sodium iodide I-131; parenteral administration of any beta emitter or photon-emitting radionuclide with a photon energy less than 150 keV
Dae Been Chough, M.D.	35.100; 35.200
George Sarris, M.D.	35.100; 35.200
Edward Skillen, D.O.	35.100; 35.200
Jun K. Chung, M.D.	35.100; 35.200
Marc J. Rosenberg, M.D.	35.100; 35.200

12. The Radiation Safety Officer for this license is Sandy J. Wolff, M.S., C.H.P., D.A.B.R.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
45-18195-01

Docket or Reference Number
030-14647

Amendment No. 26

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated August 25, 2004 (ML042510553)
    B. Letter dated April 6, 2006 (ML061090272)
    C. Letter dated May 11, 2006 (ML061420529)
    D. Letter dated March 17, 2008 (ML080870167)

For the U.S. Nuclear Regulatory Commission

Date September 8, 2008

By ***Original signed by Penny Lanzisera***

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406